- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
88 CHAPTER 3 Bladder outlet obstruction
TURP and open prostatectomy
TURP
TURP involves removal of the obstructing tissue of BPH or obstructing prostate cancer from within the prostatic urethra, leaving the compressed outer zone intact (the “surgical capsule”).
An electrically heated wire loop is used, through a resectoscope, to cut the tissue and diathermy bleeding vessels. The cut chips of prostate are pushed back into the bladder by the flow of irrigating fluid, and at the end of resection are evacuated using specially designed evacuators—a plastic or glass chamber attached to a rubber bulb that allows fluid to be flushed in and out of the bladder.
Indications for TURP
•Bothersome lower urinary tract symptoms that fail to respond to changes in life style or medical therapy
•Recurrent acute urinary retention
•Renal impairment due to BOO (high-pressure chronic urinary retention)
•Recurrent hematuria due to benign prostatic enlargement
•Bladder stones due to prostatic obstruction
Open prostatectomy
Indications
•Large prostate (>100 g)
•TURP not technically possible (e.g., limited hip abduction)
•Failed TURP (e.g., because of bleeding)
•Urethra too long for the resectoscope to gain access to the prostate
•Presence of bladder stones that are too large for endoscopic cystolitholapaxy, combined with marked enlargement of the prostate
Contraindications
•Small fibrous prostate
•Prior prostatectomy in which most of the gland has been resected or removed; this obliterates the tissue planes
•Carcinoma of the prostate
Techniques
Suprapubic (transvesical)
This is the preferred operation if enlargement of the prostate involves mainly the middle lobe. The bladder is opened, the mucosa around the protruding adenoma is incised, and the plane between the adenoma and capsule is developed to enucleate the adenoma. A 22 Fr urethral and a suprapubic catheter are left, together with a retropubic drain.
Remove the urethral catheter in 3 days and clamp the suprapubic Fr. at 6 days, removing it 24 hours later. The drain can be removed 24 hours after this (day 8).
Simple retropubic
Compared with the suprapubic (transvesical) approach, this procedure allows more precise anatomic exposure of the prostate. It allows better
TURP AND OPEN PROSTATECTOMY 89
visualization of the prostatic cavity and more accurate removal of the adenoma. Better control of bleeding points and more accurate division of the urethra can be accomplished, reducing the risk of incontinence.
As well as the contraindications noted above, the retropubic approach should not be employed when the middle lobe is very large because it is difficult to get behind the middle lobe and to incise the mucosa (safely) distal to the ureters.
The prostate is exposed by a Pfannenstiel or lower midline incision. Hemostasis is achieved before enucleating the prostate, by ligating the dorsal vein complex with sutures placed deeply through the prostate.
The prostatic capsule and adenoma are incised transversely with the cautery just distal to the bladder neck. The plane between the capsule and adenoma is found with scissors and developed with a finger. Sutures are used for hemostasis. A wedge of bladder neck is resected.
A catheter is inserted and left for 5 days and the transverse capsular incision is closed. A large tube drain (30 Fr. Robinson’s) is left for 1–2 days.
Complications
These include hemorrhage, urinary infection, and rectal perforation (close and cover with a colostomy).
90 CHAPTER 3 Bladder outlet obstruction
Acute urinary retention: definition, pathophysiology, and causes
Definition
Acute urinary retention is the painful inability to void, with relief of pain following drainage of the bladder by catheterization.
The combination of reduced or absent urine output with lower abdominal pain is not in itself enough to make a diagnosis of acute retention. Many acute surgical conditions cause abdominal pain and fluid depletion, the latter leading to reduced urine output, and this reduced urine output can give the erroneous impression that the patient is in retention when, in fact, they are not.
Thus, central to the diagnosis is the presence of a large volume of urine, which when drained by catheterization leads to resolution of the pain. What represents “large” has not been strictly defined, but volumes of 500–800 mL are typical. Volumes <500 mL should lead one to question the diagnosis. Volumes >800 mL may be defined as acute or chronic retention.
Pathophysiology
Normal micturition requires the following:
•Afferent input to the brainstem and cerebral cortex
•Coordinated relaxation of the external sphincter
•Sustained detrusor contraction
•The absence of an anatomic obstruction in the outlet of the bladder
Four broad mechanisms can lead to urinary retention:
•Increased urethral resistance (i.e., BOO)
•Low bladder pressure (i.e., impaired bladder contractility)
•Interruption of sensory or motor innervation of bladder
•Central failure of coordination of bladder contraction with external sphincter relaxation
Causes in men
Causes include benign prostatic enlargement, malignant enlargement of the prostate, urethral stricture, and prostatic abscess (see also Box 3.2).
Urinary retention in men is either spontaneous or precipitated by an event. Precipitated retention is less likely to recur once the event causing it has been removed. Spontaneous retention is more likely to recur after a trial of catheter removal and more likely to require definitive treatment (e.g., TURP).
Precipitated retention can be caused by events such as anesthetic and other drugs (anticholinergics, sympathomimetic agents such as ephedrine in nasal decongestants), nonprostatic abdominal or perineal surgery, and immobility following surgical procedures.
ACUTE URINARY RETENTION 91
Box 3.2 Causes of acute urinary retention in either sex
•Hematuria leading to clot retention
•Drugs (e.g., anticholinergics, sympathomimetic agents)
•Pain (adrenergic stimulation of the bladder neck)
•Postoperative retention (see below)
•Sacral cord (S2–4) injury
•Sacral (S2–4) nerve or compression or damage, resulting in detrusor areflexia—cauda equina compression (due to prolapsed L2–L3 disc or L3–L4 intervertebral disc pressing on sacral nerve roots of the cauda equina, trauma to vertebrae, or tumors [benign or metastatic])
•Suprasacral spinal cord injury (results in loss of coordination of external sphincter relaxation with detrusor contraction—detrusor- sphincter dyssynergia (DSD)—so external sphincter contracts when bladder contracts)
•Radical pelvic surgery damaging pelvic parasympathetic plexus (radical hysterectomy, abdominoperineal resection): unilateral injury to pelvic plexus (preganglionic parasympathetic and postganglionic sympathetic neurons) denervates motor innervation of detrusor muscle
•Pelvic fracture rupturing urethra (more likely in men than in women)
•Neurotropic viruses involving sensory dorsal root ganglia of S2–4 (herpes simplex or zoster)
•Multiple sclerosis (can affect any part of the CNS—Fig. 3.2); retention caused by detrusor areflexia or DSD
•Transverse myelitis
•Diabetic cystopathy (causes sensory and motor dysfunction)
•Damage to dorsal columns of spinal cord causing loss of bladder sensation (tabes dorsalis, pernicious anemia)
Causes in women
These include pelvic prolapse (cystocele, rectocele, uterine); urethral stricture; urethral diverticulum; post-surgery for stress incontinence; pelvic masses (e.g., ovarian masses); and Fowler syndrome.
Fowler syndrome
Increased electromyographic activity can be recorded in the external urethral sphincters of these women (which on ultrasound are of increased volume) and is hypothesized to cause impaired relaxation of the external sphincter.
Fowler syndrome occurs in premenopausal women, often in association with polycystic ovaries.
Risk factors for postoperative retention
Risk factors include instrumentation of the lower urinary tract; surgery to the perineum or anorectum; gynecological surgery; bladder overdistension; reduced sensation of bladder fullness; pre-existing prostatic obstruction; and epidural anesthesia. Postpartum retention is not uncommon, particularly with epidural anesthesia and instrumental delivery.
92 CHAPTER 3 Bladder outlet obstruction
Figure 3.2 MRI of cervical and sacral cord in a young patient presenting with urinary retention. The patient had undiagnosed MS. Signal changes are seen in the cervical, thoracic, and lumbosacral cord.
This page intentionally left blank
94 CHAPTER 3 Bladder outlet obstruction
Acute urinary retention: initial and definitive management
Initial management
Urethral catheterization is used to relieve pain (suprapubic catheterization if urethral route not possible). Record the volume drained—this confirms the diagnosis, determines subsequent management, and provides prognostic information on outcome from this treatment.
Definitive management in men
Discuss trial without catheter (TWOC) with the patient. Precipitated retention often does not recur; spontaneous retention often does. Half of patients with spontaneous retention will experience a second episode of retention within the next week or so, and 70% within the next year.
A maximum flow rate (Qmax) <5 mL/s and low voiding detrusor pressure predicts subsequent retention. Thus, while most patients will require definitive treatment (e.g., TURP), a substantial minority will not need surgery.
Options to avoid TURP
•Prostate-shrinking drugs followed by a voiding trial several months later (5A-reductase inhibitors in those with benign-feeling prostates, LHRH agonists in those with malignant-feeling prostates on DRE, confirmed by TRUS-guided prostate biopsy)
•Prostatic stents
•Long-term urethral or suprapubic catheter
•Clean, intermittent self-catheterization (CISC) is not a realistic option for most men, but some will be able and happy to do this.
Definitive management in women
Use CISC either until normal voiding function recovers or permanently if it does not. For Fowler syndrome use sacral neuromodulation (e.g., Medtronic InterStim).
Risks and outcomes of TURP for retention
Relative risks of TURP for retention vs. TURP for lower urinary tract symptoms (LUTS) are as follows: postoperative complications 26:1; blood transfusion 2.5:1; in-hospital death 3:1.1
High retention volume, greater age, and low maximum detrusor pressure are predictive for failure to void after TURP; 10% of those with acute retention of urine and 40% of those with chronic retention fail to void after initial post-turp. Overall, 1% of men will fail to void after subsequent voiding trial and will require long-term catheterization.2
1 Pickard R, Emberton M, Neal D (1998). The management of men with acute urinary retention. Br J Urol 81:712–720.
2 Reynard JM (1999). Failure to void after transurethral resection of the prostate and mode of presentation. Urology 53:336–339.
This page intentionally left blank